Esterase D and gamma 1 actin level might predict results of induction therapy in patients with acute myeloid leukemia without and with maturation
Maciej Kaźmierczak(Silesian University of Technology), Mieczysław Komarnicki(Poznan University of Medical Sciences), Anna Czyż(Wroclaw Medical University), Michał Michalak(Poznan University of Medical Sciences), Krzysztof Lewandowski(Poznan University of Medical Sciences), Magdalena Łuczak(Institute of Bioorganic Chemistry, Polish Academy of Sciences), Michał Gniot(Poznan University of Medical Sciences), Luiza Handschuh(Institute of Bioorganic Chemistry, Polish Academy of Sciences), Małgorzata Jarmuż‐Szymczak(Poznan University of Medical Sciences), Marek Figlerowicz(Poznań University of Technology)
Cited by 25
Related Papers
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia
|Blood Advances|2020|109
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial
|Journal of Clinical Oncology|2022|93
Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR
|International Journal of Oncology|2017|80